|
2025-03-27 |
2025-03-25 |
AP
Achat planifié
|
Combs Andrew
Chief Chemistry Officer
Dirigeant
|
100 000
+26.3%
0,69
69 250 USD
|
100 000
+26.3%
|
0,69
|
69 250 USD
|
|
|
2025-03-27 |
2025-03-25 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
675 000
+51.0%
0,69
467 438 USD
|
675 000
+51.0%
|
0,69
|
467 438 USD
|
|
|
2025-03-24 |
2025-03-21 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
15 000
+1.1%
0,73
10 959 USD
|
15 000
+1.1%
|
0,73
|
10 959 USD
|
|
|
2025-03-24 |
2025-03-20 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
5 416
+0.4%
0,73
3 950 USD
|
5 416
+0.4%
|
0,73
|
3 950 USD
|
|
|
2025-03-18 |
2025-03-17 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
9 106
+0.7%
0,75
6 829 USD
|
9 106
+0.7%
|
0,75
|
6 829 USD
|
|
|
2025-03-18 |
2025-03-14 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
29 999
+2.4%
0,75
22 631 USD
|
29 999
+2.4%
|
0,75
|
22 631 USD
|
|
|
2025-03-14 |
2025-03-13 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
50 000
+4.1%
0,72
35 820 USD
|
50 000
+4.1%
|
0,72
|
35 820 USD
|
|
|
2025-03-14 |
2025-03-12 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
47 500
+4.1%
0,71
33 744 USD
|
47 500
+4.1%
|
0,71
|
33 744 USD
|
|
|
2025-01-03 |
2024-12-31 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
5 000
+3.6%
1,21
6 044 USD
|
5 000
+3.6%
|
1,21
|
6 044 USD
|
|
|
2025-01-02 |
2024-12-30 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
10 000
+7.8%
1,20
12 000 USD
|
10 000
+7.8%
|
1,20
|
12 000 USD
|
|
|
2024-12-26 |
2024-12-23 |
A
Achat
|
Combs Andrew
Chief Chemistry Officer
Dirigeant
|
60 000
+18.9%
1,37
82 002 USD
|
60 000
+18.9%
|
1,37
|
82 002 USD
|
|
|
2024-12-26 |
2024-12-20 |
AP
Achat planifié
|
Combs Andrew
Chief Chemistry Officer
Dirigeant
|
3 075
+1.0%
1,15
3 536 USD
|
3 075
+1.0%
|
1,15
|
3 536 USD
|
|
|
2024-12-20 |
2024-12-19 |
A
Achat
|
Lim Bryant David
CLO, Interim CFO, Corp Sec.
Dirigeant
|
25 000
+1041.7%
0,91
22 638 USD
|
25 000
+1041.7%
|
0,91
|
22 638 USD
|
|
|
2024-12-20 |
2024-12-19 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
6 888
+5.7%
0,89
6 116 USD
|
6 888
+5.7%
|
0,89
|
6 116 USD
|
|
|
2024-12-20 |
2024-12-18 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
100 000
+9.4%
0,93
93 210 USD
|
100 000
+9.4%
|
0,93
|
93 210 USD
|
|
|
2023-05-26 |
2023-05-25 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
900
+0.1%
5,31
4 779 USD
|
900
+0.1%
|
5,31
|
4 779 USD
|
|
|
2023-05-26 |
2023-05-24 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
1 000
+0.1%
5,01
5 011 USD
|
1 000
+0.1%
|
5,01
|
5 011 USD
|
|
|
2023-05-25 |
2023-05-24 |
A
Achat
|
Lim Bryant David
Chief Legal Officer, Corp Sec.
Dirigeant
|
2 400
+inf%
5,39
12 936 USD
|
2 400
+inf%
|
5,39
|
12 936 USD
|
|
|
2023-05-25 |
2023-05-23 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
11 856
+1.1%
5,63
66 749 USD
|
11 856
+1.1%
|
5,63
|
66 749 USD
|
|
|
2023-05-25 |
2023-05-23 |
AP
Achat planifié
|
Chardonnet Laurent
Chief Financial Officer
Dirigeant
|
5 000
+13.5%
5,50
27 500 USD
|
5 000
+13.5%
|
5,50
|
27 500 USD
|
|
|
2023-05-24 |
2023-05-22 |
A
Achat
|
ORBIMED ADVISORS LLC
Administrateur non-exécutif
Actionnaire important
|
869 565
+9.4%
5,75
4 999 999 USD
|
869 565
+9.4%
|
5,75
|
4 999 999 USD
|
|
|
2023-05-24 |
2023-05-22 |
A
Achat
|
Bonita David P
Administrateur non-exécutif
Actionnaire important
|
869 565
+9.4%
5,75
4 999 999 USD
|
869 565
+9.4%
|
5,75
|
4 999 999 USD
|
|
|
2023-04-06 |
2023-04-06 |
V
Vente
|
Huang Jane
President, CMO
Dirigeant
|
13 280
-35.4%
6,12
81 274 USD
|
13 280
-35.4%
|
6,12
|
81 274 USD
|
|
|
2022-12-21 |
2022-12-20 |
A
Achat
|
Vaddi Krishna
CEO
Administrateur exécutif
|
19 188
+18.9%
5,13
98 446 USD
|
19 188
+18.9%
|
5,13
|
98 446 USD
|
|
|
2022-12-12 |
2022-12-08 |
AP
Achat planifié
|
Chardonnet Laurent
Chief Financial Officer
Dirigeant
|
10 000
+38.7%
4,76
47 600 USD
|
10 000
+38.7%
|
4,76
|
47 600 USD
|
|
|
2022-06-01 |
2022-06-01 |
A
Achat
|
Chardonnet Laurent
Chief Financial Officer
Dirigeant
|
10 000
+69.0%
4,23
42 300 USD
|
10 000
+69.0%
|
4,23
|
42 300 USD
|
|
|
2021-12-17 |
2021-12-15 |
VP
Vente planifiée
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Dirigeant
|
28 751
-98.5%
13,00
373 763 USD
|
28 751
-98.5%
|
13,00
|
373 763 USD
|
|
|
2021-12-15 |
2021-12-14 |
A
Achat
|
Combs Andrew
EVP, Head of Chemistry
Dirigeant
|
4 000
+1.5%
11,60
46 400 USD
|
4 000
+1.5%
|
11,60
|
46 400 USD
|
|
|
2021-12-15 |
2021-12-13 |
A
Achat
|
Combs Andrew
EVP, Head of Chemistry
Dirigeant
|
4 000
+1.5%
12,12
48 480 USD
|
4 000
+1.5%
|
12,12
|
48 480 USD
|
|
|
2021-11-18 |
2021-11-16 |
VP
Vente planifiée
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Dirigeant
|
400
-47.4%
16,43
6 570 USD
|
400
-47.4%
|
16,43
|
6 570 USD
|
|
|
2021-11-18 |
2021-11-16 |
VP
Vente planifiée
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Dirigeant
|
28 351
-97.1%
15,87
449 962 USD
|
28 351
-97.1%
|
15,87
|
449 962 USD
|
|
|
2021-10-06 |
2021-10-05 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
1 289
-100.0%
32,06
41 330 USD
|
1 289
-100.0%
|
32,06
|
41 330 USD
|
|
|
2021-10-06 |
2021-10-05 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
7 803
-85.8%
31,30
244 257 USD
|
7 803
-85.8%
|
31,30
|
244 257 USD
|
|
|
2021-10-06 |
2021-10-05 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
5 908
-39.4%
30,26
178 762 USD
|
5 908
-39.4%
|
30,26
|
178 762 USD
|
|
|
2021-06-09 |
2021-06-07 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
12 700
-100.0%
32,73
415 665 USD
|
12 700
-100.0%
|
32,73
|
415 665 USD
|
|
|
2021-06-09 |
2021-06-07 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
900
-6.6%
31,62
28 462 USD
|
900
-6.6%
|
31,62
|
28 462 USD
|
|
|
2021-06-09 |
2021-06-07 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
1 400
-9.3%
30,35
42 496 USD
|
1 400
-9.3%
|
30,35
|
42 496 USD
|
|
|
2021-05-27 |
2021-05-25 |
VP
Vente planifiée
|
Piper Brian
Chief Financial Officer
Dirigeant
|
399
-100.0%
36,09
14 401 USD
|
399
-100.0%
|
36,09
|
14 401 USD
|
|
|
2021-05-27 |
2021-05-25 |
VP
Vente planifiée
|
Piper Brian
Chief Financial Officer
Dirigeant
|
1 736
-81.3%
35,45
61 536 USD
|
1 736
-81.3%
|
35,45
|
61 536 USD
|
|
|
2021-05-27 |
2021-05-25 |
VP
Vente planifiée
|
Piper Brian
Chief Financial Officer
Dirigeant
|
3 088
-59.1%
34,11
105 338 USD
|
3 088
-59.1%
|
34,11
|
105 338 USD
|
|
|
2021-05-27 |
2021-05-25 |
VP
Vente planifiée
|
Piper Brian
Chief Financial Officer
Dirigeant
|
3 110
-37.3%
33,53
104 263 USD
|
3 110
-37.3%
|
33,53
|
104 263 USD
|
|
|
2021-05-11 |
2021-05-07 |
VP
Vente planifiée
|
Scherle Peggy
Chief Scientific Officer
Dirigeant
|
200
-0.1%
41,85
8 370 USD
|
200
-0.1%
|
41,85
|
8 370 USD
|
|
|
2021-05-11 |
2021-05-07 |
VP
Vente planifiée
|
Scherle Peggy
Chief Scientific Officer
Dirigeant
|
5 836
-3.3%
41,14
240 090 USD
|
5 836
-3.3%
|
41,14
|
240 090 USD
|
|
|
2021-05-11 |
2021-05-07 |
VP
Vente planifiée
|
Scherle Peggy
Chief Scientific Officer
Dirigeant
|
3 964
-2.2%
40,30
159 732 USD
|
3 964
-2.2%
|
40,30
|
159 732 USD
|
|
|
2021-05-10 |
2021-05-05 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
1 109
-100.0%
41,07
45 545 USD
|
1 109
-100.0%
|
41,07
|
45 545 USD
|
|
|
2021-05-10 |
2021-05-05 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
10 476
-90.4%
40,30
422 148 USD
|
10 476
-90.4%
|
40,30
|
422 148 USD
|
|
|
2021-05-10 |
2021-05-05 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
3 415
-22.8%
39,36
134 399 USD
|
3 415
-22.8%
|
39,36
|
134 399 USD
|
|
|
2021-04-30 |
2021-04-29 |
VP
Vente planifiée
|
Pierce Christopher
EVP and Chief of Business Oper
Dirigeant
|
3 295
-46.8%
40,29
132 765 USD
|
3 295
-46.8%
|
40,29
|
132 765 USD
|
|
|
2021-04-30 |
2021-04-29 |
VP
Vente planifiée
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Dirigeant
|
3 223
-87.9%
40,29
129 853 USD
|
3 223
-87.9%
|
40,29
|
129 853 USD
|
|
|
2021-04-29 |
2021-04-27 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
1 711
-100.0%
36,11
61 791 USD
|
1 711
-100.0%
|
36,11
|
61 791 USD
|
|
|
2021-04-29 |
2021-04-27 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
15 601
-90.1%
35,68
556 580 USD
|
15 601
-90.1%
|
35,68
|
556 580 USD
|
|
|
2021-04-29 |
2021-04-27 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
7 688
-30.8%
34,66
266 478 USD
|
7 688
-30.8%
|
34,66
|
266 478 USD
|
|
|
2021-04-21 |
2021-04-19 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
4 000
-100.0%
31,27
125 077 USD
|
4 000
-100.0%
|
31,27
|
125 077 USD
|
|
|
2021-04-21 |
2021-04-19 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
21 000
-84.0%
30,82
647 273 USD
|
21 000
-84.0%
|
30,82
|
647 273 USD
|
|
|
2021-04-15 |
2021-04-08 |
VP
Vente planifiée
|
Pierce Christopher
EVP and Chief of Business Oper
Dirigeant
|
200
-5.1%
40,00
8 000 USD
|
200
-5.1%
|
40,00
|
8 000 USD
|
|
|
2021-04-15 |
2021-04-08 |
VP
Vente planifiée
|
Scherle Peggy
Chief Scientific Officer
Dirigeant
|
1 669
-1.0%
39,57
66 040 USD
|
1 669
-1.0%
|
39,57
|
66 040 USD
|
|
|
2021-04-15 |
2021-04-08 |
VP
Vente planifiée
|
Scherle Peggy
Chief Scientific Officer
Dirigeant
|
669
-0.4%
38,97
26 073 USD
|
669
-0.4%
|
38,97
|
26 073 USD
|
|
|
2021-04-15 |
2021-04-08 |
VP
Vente planifiée
|
Scherle Peggy
Chief Scientific Officer
Dirigeant
|
875
-0.5%
37,72
33 003 USD
|
875
-0.5%
|
37,72
|
33 003 USD
|
|
|
2021-04-15 |
2021-04-08 |
VP
Vente planifiée
|
Scherle Peggy
Chief Scientific Officer
Dirigeant
|
1 417
-0.8%
36,97
52 387 USD
|
1 417
-0.8%
|
36,97
|
52 387 USD
|
|
|
2021-04-09 |
2021-04-07 |
VP
Vente planifiée
|
Scherle Peggy
Chief Scientific Officer
Dirigeant
|
200
-0.1%
40,30
8 060 USD
|
200
-0.1%
|
40,30
|
8 060 USD
|
|
|
2021-04-09 |
2021-04-07 |
VP
Vente planifiée
|
Scherle Peggy
Chief Scientific Officer
Dirigeant
|
6 881
-3.8%
39,63
272 679 USD
|
6 881
-3.8%
|
39,63
|
272 679 USD
|
|
|
2021-04-09 |
2021-04-07 |
VP
Vente planifiée
|
Scherle Peggy
Chief Scientific Officer
Dirigeant
|
8 289
-4.4%
39,02
323 405 USD
|
8 289
-4.4%
|
39,02
|
323 405 USD
|
|
|
2021-04-09 |
2021-04-07 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
7 083
-100.0%
39,69
281 116 USD
|
7 083
-100.0%
|
39,69
|
281 116 USD
|
|
|
2021-04-09 |
2021-04-07 |
VP
Vente planifiée
|
Mauro David J
Chief Medical Officer
Dirigeant
|
8 300
-54.0%
39,03
323 908 USD
|
8 300
-54.0%
|
39,03
|
323 908 USD
|
|
|
2020-09-29 |
2020-09-29 |
A
Achat
|
Combs Andrew
EVP, Head of Chemistry
Dirigeant
|
1 000
+0.4%
19,00
19 000 USD
|
1 000
+0.4%
|
19,00
|
19 000 USD
|
|
|
2020-09-29 |
2020-09-29 |
A
Achat
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Dirigeant
|
444
+inf%
19,00
8 436 USD
|
444
+inf%
|
19,00
|
8 436 USD
|
|
|
2020-09-29 |
2020-09-29 |
A
Achat
|
Dier Mardi
Administrateur non-exécutif
|
10 000
+inf%
19,00
190 000 USD
|
10 000
+inf%
|
19,00
|
190 000 USD
|
|
|
2020-09-29 |
2020-09-29 |
A
Achat
|
Pierce Christopher
EVP and Chief of Business Oper
Dirigeant
|
3 750
+inf%
19,00
71 250 USD
|
3 750
+inf%
|
19,00
|
71 250 USD
|
|
|
2020-09-29 |
2020-09-25 |
A
Achat
|
ORBIMED ADVISORS LLC
Administrateur non-exécutif
Actionnaire important
|
710 500
+343.4%
19,00
13 499 500 USD
|
710 500
+343.4%
|
19,00
|
13 499 500 USD
|
|
|
2020-09-29 |
2020-09-25 |
A
Achat
|
ORBIMED ADVISORS LLC
Administrateur non-exécutif
Actionnaire important
|
526 300
+inf%
19,00
9 999 700 USD
|
526 300
+inf%
|
19,00
|
9 999 700 USD
|
|
